2026 Interim Report
Filed with HKEX · Stock code 2181 · · 89 pages · English
2 Corporate Information 4 Financial Highlights 5 Corporate Profile 13 Management Discussion and Analysis 45 Other Information 54 Independent Review Report 56 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 57 Interim Condensed Consolidated Statement of Financial Position 59 Interim Condensed Consolidated Statement of Changes in Equity 60 Interim Condensed
Earlier from Mabpharm
- Third Amended and Restated memorandum and articles of association
- Voluntary announcement approval from the national medical products administration on the new drug application (nda) of our pipeline product, CMAB807X (denosumab injection)
Later from Mabpharm
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Mabpharm into a list and get an email when it puts out news.
Follow Mabpharm